Diagnostik und Therapie der Polyneuropathie

H. Grehl

doi:10.1055/s-0038-1628546

Nervenheilkunde, Table of Contents

Nervenheilkunde 2013; 32(09): 651-659
DOI: 10.1055/s-0038-1628546

Update

Schattauer GmbH

Diagnostik und Therapie der Polyneuropathie

UpdateDiagnosis and therapy of polyneuropathiesUpdate

Authors

H. Grehl

¹Neurologische Klinik, Klinikum Niederrhein, Duisburg

Abstract

Zusammenfassung

Polyneuropathien sind häufige Erkrankungen des peripheren Nervensystems, die eine Vielzahl von Ursachen haben können. Einer sorgfältigen Ursachendiagnostik sollte immer eine möglichst genaue klinische und neurophysiologische Zuordnung vorausgehen, um die weiterführende Labordiagnostik zielgerichtet einsetzen zu können. Die folgende Arbeit gibt eine Übersicht über die aktuelle Diagnostik und Therapie klinisch relevanter Neuropathieformen.

Summary

Polyneuropathies are common disorders of the peripheral nervous system with a large variety of causes. The search for the etiology should always start with a careful clinical and neurophysiological examination in order to assess the laboratory examinations efficiently. The following paper provides an overview of diagnosis and therapy of clinically relevant polyneuropathies.

Schlüsselwörter

Polyneuropathie - Diagnostik - Therapie

Keywords

Polyneuropathy - diagnosis - therapy

Full Text

References

Literatur
1 Nakamura T, Hashiguchi A, Suzuki S, Uozumi K, Tokunaga S, Takashima H. Vincristine exacerbates asymptomatic Charcot-Marie-tooth disease with a novel EGR2 mutation. Neurogenetics 2012; 13 (01) 77-82.
2 Collins MP. et al. Peripheral Nerve Society Guideline on the classification, diagnosis, investigation, and immunosuppressive therapy of non-systemic vasculitic neuropathy: executive summary. J Peripher Nerv Syst 2010; 15 (03) 176-184.
3 Chawla J, Gruener G. Management of critical illness polyneuropathy and myopathy. Neurol Clin 2010; 28 (04) 961-77.
4 Koike H. et al. Clinicopathological features of acute autonomic and sensory neuropathy. Brain 2010; 133 (10) 2881-96.
5 Latov N. et al. Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. Arch Neurol 2010; 67 (07) 802-7.
6 Donofrio PD. et al. Safety and tolerability of immune globulin intravenous in chronic inflammatory demyelinating polyradiculoneuropathy. Arch Neurol 2010; 67 (09) 1082-8.
7 Leitch MM, Sherman WH, Brannagan TH. Distal acquired demyelinating symmetric polyneuropathy progressing to classic chronic inflammatory demyelinating polyneuropathy and response to fludarabine and cyclophosphamide. Muscle & Nerve 2012; 47 (02) 292-6.
8 Vallat JM. et al. Chronic inflammatory demyelinating polyradiculoneuropathy: diagnostic and therapeutic challenges for a treatable condition. Lancet Neurol 2010; 09 (04) 402-12.
9 Gorson KC. An update on the management of chronic inflammatory demyelinating polyneuropathy. Therapeutic Advances in Neurological Disorders 2012; 05 (06) 359-373.
10 Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradicu- loneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society First Revision. J Peripher Nerv Syst 2010; 15 (01) 1-9.
11 Saporta ASD, Sottile SL, Miller LJ, Feely SME, Siskind CE, Shy ME. Charcot-Marie-Tooth disease subtypes and genetic testing strategies. Annals of Neurology 2010; 69 (01) 22-33.
12 Albers JW. et al. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care 2010; 33 (05) 1090-6.
13 Perkins BA. et al. Short-term metabolic change is associated with improvement in measures of diabetic neuropathy: a 1-year placebo cohort analysis. Diabet Med 2010; 27 (11) 1271-9.
14 Maritz J. et al. HIV neuropathy in South Africans: frequency, characteristics, and risk factors. Muscle Nerve 2010; 41 (05) 599-606.
15 Vivithanaporn P. et al. Neurologic disease burden in treated HIV/AIDS predicts survival: a population-based study. Neurology 2010; 75 (13) 1150-8.
16 Sittl RR. et al. Anticancer drug oxaliplatin induces acute cooling-aggravated neuropathy via sodium channel subtype Na(V)1.6-resurgent and persistent current. Proc Natl Acad Sci USA 2012; 109 (17) 6704-9.
17 Kawagashira Y. et al. Differential response to intravenous immunoglobulin (IVIg) therapy among multifocal and polyneuropathy types of painful diabetic neuropathy. J Clin Neurosci 2010; 17 (08) 1003-8.